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1751-31 Lovastatin and Probucol for the Prevention of
Restenosls After Coronary Angioplasty
groups in baseline clinical characteristics. The acute gain (0.96 ± 0.42 mm,
1.03 ± 0.40 mm) and late loss (0.36 ± 0.51 mm, 0.36 ± 0.57 mm) were
similar in the Fraxiparine and aspirin groups. Restenosis, defined as a binary
variable (stenosis >50% at angiographic follow-up) occurred in 41 % of the
Fraxiparine treated and 38% of the aspirin treated group (p = 0.69). At six
months major clinical event rates, death (1 % vs 2%), acute myocardial in-
farction (4% vs 2%1 and repeat revascularization 126% vs 26%) were similar
in both groups.
Despite, 3 days of pretreatment and 3 months of treatment with low
molecular weight heparin (Fraxiparine), no statistical differences were ob-
served in angiographic or clinical end points.
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Rapid Angiographlc Progression of "Target" and
"Non-target" Stenoses in Patients Awaiting Coronary
Angioplasty
Juan Carlos Kaski, Lilia Chen, Michael Chester. St. George's Hospital Medical School,
London, U.K.
Coronary angioplasty (PTCA) is effective therapy for angina pectoris but coro-
nary events occur after successful PTCA which may be caused by both
restenosis and progression of mild pre-existing, "non-target", stenoses. To
compare the short-term evolution of "target" versus "non-target" stenoses
in patients awaiting PTCA, we prospectively studied 161 consecutive sta-
ble angina patients (124 men and 37 women). After diagnostic angiography,
"target" stenoses for PTCA and "non-target" lesions were identified. Patients
were put on a routine waiting list and followed up regularly until repeat coro-
nary arteriography (mean ± SD: 7 ± 3 months). which was performed im-
mediately preceding angioplasty (138 patients) or soon after acute coronary
events (23 patients) when these occurred. Stenosis diameters were mea-
sured using computerized arteriography. Progression was defined as 2:20%
diameter reduction, new total occlusion, or development of "new" stenoses
2:30%. At study entry, diameters of target (n = 207) and non-target (n = 184)
lesions were 68 ± 9% and 38 ± 9%, respectively (p < 0.001). Disease pro-
gression occurred in 33 patients (20%). in whom 18 target (9%) and 15 non-
target stenoses (8%) progressed and 7 new lesions (1 total occlusion) devel-
oped. Total occlusion developed in 15 of the 18183%) target and in 6 of the
15 (40%) non-target stenoses; (p = 0.03). During follow up, 3 patients (2%)
had a myocardial infarction and 20 (12%) developed unstable angina. These
events were associated with progression of target stenoses in 10 patients,
of non-target stenoses in 7 patients, and with new lesions in one patient. In
5 patients events were not associated with stenosis progression.
Thus a similar proportion of target and non-target lesions progressed
rapidly. Target stenoses, however, were more likely to progress to total oc-
clusion than non-target lesions. Progression of non-target stenoses may con-
tribute to recurrence of angina and new coronary events after successful
angioplasty and their role should be considered when developing strategies
aimed at improving survival after angioplasty.
1751-61 Multiple Repeat Coronary Angioplasty for Final
Lesion Patency
Hidemasa Kitazume, Ichiro Kubo, Yoshio Ageishi, Toru Iwama, Akio Suzuki. Bokuto
Hospital, Tokyo, Japan
To demonstrate that multiple repeat coronary angioplasty can be solely uti-
lized to achieve final lesion patency after restenosis, such a protocol was
prospectively applied for restenosis since 1983. Bypass surgery was only
considered for 1) new left main trunk lesions, 21 symptomatic restenosis
where angioplasty was either unsuccessful or unsuitable, and 3) patient
preference. Between 1983 and 1992, 1455 lesions (acute myocardial infarc-
tion or total occlusion excluded) were successfully dilated for the first time.
Although only 941 (68%) of the 1385 lesions studied showed satisfactory
patency (:::70% stenosis) after the first procedure, 93% (1248/1345 stud-
ied) showed satisfactory patency after repeating angioplasty up to 3 times
and 94% (1268/1354 studied) after repetition up to 6 times. Only 23 lesions
11.6%) required 4 or more procedures and 20 of them showed final patency.
Disease aggravation (either impossible or failed repeat angioplasty, acute in-
farction, or sudden death) occurred in 43 lesions (3.2%). Bypass grafts were
done for 11 lesions of 7 patients, mostly due to disease progression at the
left main trunk.
1(1%)
1(1%)
22(29%)
3(4%)
Placebo (n = 76)
1(1%)
3(2%)
51 (31%)
7(4%)
Active (n ~ 163)
Death
Myocardial Infarction
Repeat PTCA
Bypass Surgery
Patricia G. Cavera, James H. O'Keefe, Jr., Gregg W. Stone, Ben D. McCallister, Jr.,
Cheryl Dreiling, Robert Ligon, Ray L. Kacich. Mid America Heart Institute, Kansas City,
MO
We hypothesized that combination lipid lowering therapy (Lovastatin) and
anti-oxidant (Probucol) therapy might reduce restenosis following coronary
angioplasty(pTCAI. To address this question, 239 patients (pts) were enrolled
in a multi-center, randomized trial whereby 2 out of 3 pts received Lovas-
tatin 20 mg bid and Probucol 500 mg bid in combination; lout of 3 pts was
randomized to double placebo. Pts were treated in a blinded fashion for 6
months. Total cholesterol (154 vs 211), LDL 198 vs 141) and HDL (31 vs 42)
were lower in treated compared with placebo patients. Serious adverse ef-
fects from the medications were not observed.
EVENTS WITHIN 6 MONTHS
Quantitative coronary angiography was available in 147 lesions, the mean
loss in luminal diameter was 27% ± 31 % and 28% ± 34% in treated and
placebo groups.
Conclusion: Combination Lovastatin and Probucol: 1) reduced total choles-
terol (27%). LDL (29%) and HDL (27%) levels, but 2) did not prevent resteno-
sis or clinical events during the first six months post-angioplasty.
(PTCA). Reducing platelet accumulation at PTCA sites may attenuate NP
and restenosis. Single antiplatelet agents are not effective, due to multiple
platelet activation pathways. Previous work suggested that combined antag-
onism of 2 mediators of platelet aggregation -thromboxane A2 (byridogre/)
and serotonin (by kemnserin). could reduce platelet-thrombus formation and
lessen NP We therefore tested the hypothesis that combined treatment with
3 agents (ridogrel, kemnserin. and an ADP antagonist - clopidogre/l would
be more effective in reducing NP after PTCA. We studied 18 dogs with coro-
nary flow probes and plastic constrictors chronically implanted on LAD arter-
ies. All dogs underwent LAD PTCA and were sacrificed after 8 weeks of mon-
itoring. Eight dogs were controls, while 10 dogs were treated with combined
anti platelet therapy for 3 weeks before and 3 weeks after PTCA. Compared to
controls, ex vivo platelet aggregation was virtually abolished in treated dogs,
and bleeding times during treatment were greater (>720 vs 119 ± 4 sec, p <
0.001). Cyclic flow variations (CFVs) after PTCA, from repetitive accumulation
and dislodgement of platelet aggregates at PTCA sites, occurred in 7/8 con-
trols but in only 1/10 treated dogs (p < 0.01). Platelet counts and hematocrit
values were not different between treated and control groups. Quantitative
coronary artery histology revealed that neointimal area was threefold less in
the treated group (0.18 ± 0.07 cm2 vs 0.52 ± 0.12, P = 0.032), as was the
percent lumen stenosis (13 ± 4% vs 40 ± 13%, P = 0.06).
Conclusion: Combination antiplatelet therapy with these 3 antagonists in-
hibited several relevant measures of platelet function and reduced neointi-
mal proliferation in a canine coronary artery angioplasty model.
Jean-Marc Lablanche, The FACT investigators. France, Belgium, Spain
Restenosis after coronary angioplasty is a multifactorial process that may
involve elastic recoil, thrombus incorporation, smooth muscle cell prolifera-
tion, and late vascular remodeling. Fraxiparine (nadroparin) is a low molecular
weight heparin derivative that has potent antithrombotic and antiproliferative
properties in animal models.
The FACT (Fraxiparine Angioplastie Coronaire Transluminale) study is a
multicentre double-blind randomised trial designed to compare the effects
of treatment with Fraxiparine or aspirin on the occurrence of restenosis af-
ter coronary balloon angioplasty. All patients received aspirin (250 mg, daily)
before coronary angioplasty. Therapeutic doses of unfractionated heparin
were used during coronary angioplasty in both groups. The active treatment
group received subcutaneous injections of Fraxiparine (0.6 ml) daily for 3
days before coronary angioplasty that was continued for 3 months. The con-
trol group was treated with aspirin (250 mg) daily for 3 months.
In total, 354 patients were randomized and constitute the intention-to-treat
population. Angiographic follow-up was performed in 91 % of patients with
successful procedures at 3 months. There were no differences between
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1751-41 Low Molecular Weight Heparin in the Prevention of
Restenosis After Coronary Angioplasty. Results of
the FACT Study
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Dilatation Patent Mild Re-do Grafts Medical Aggra- With- Cumulative
(stenosis) (G-50%) (55-70%1 (75%-) 175%-) 175%-) vated# drawal G-70% No.'"
1st 874 67 384 9 16 32 73 941 1382
2nd 221 22 97 a 6 7 31 1184 1351
3rd 53 11 23 a 1 3 6 1248 1345
4th 11 1 8 1 a 1 a 1261 1345
5th 3 3 2 a a a a 1267 1345
6th 1 a a 1 a a a 1268 1345
*:1763- 1: Withdrawal. # :sudden death. acute infarction or irreversible occlusion
Conclusion: These findings indicate that 1) repeat angioplasty can be the
main treatment strategy for restenosis, 2) multiple repeat angioplasties (up
to 6 times) can be effective and rarely aggravate coronary anatomy and 31
disease aggravation must be prevented to improve the final patency rate of
repeat ang ioplasty.
Linear ultrasound contrast echo data was digitally stored on optical disc and
quantified using a specially developed software package. Measured param-
eters were peak contrast effect (P), area under the contrast echo curve (A).
time to peak contrast effect, contrast half-time and mean transit time. Con-
trast effect in the myocardial bed of the index artery Ii) was also compared
with that in a reference bed supplied by a normal artery (r). Nine patients
("viable group") had an improvement in echo score at 1 month while 5 pa-
tients ("non-viable" group) had no improvement. The "viable" patients had an
improvement in ejection fraction (52.1 % to 55.5%, P < 0.02) as well as wall
motion index score (1.4 to 1.1, p < 0.04) while the "non-viable" patients had
no significant improvement in either parameter (49.0% to 42.8% and 1.5 to
1.61. Significant contrast data was:
Pli) Pli)!P(rl Ali) A(iI/A(r)
'Vlable" 184 0.54 66.1 0.51
"Non-viable" 064 0.22 20.0 0.22
P value p < 0.04 P < 0.01 P < 0.02 P < 0.05
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P and A were significantly greater in the index myocardial bed in the "vi-
able" group compared to the "non-viable" group. Despite a patent epicardial
index coronary artery, 4/5 patients in the "non-viable" group demonstrated
minimal contrast effect in the index myocardial segment. These initial results
suggest that ICE prior to PTCA may be rapidly used to predict improvement in
both regional and global left ventricular function. The contrast data is additive
to that obtained by angiography and identification of a contrast "watershed"
value should enable a valuable echo predictor of myocardial viability.
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1752-31 Evaluation of Regional Myocardial Perfusion in Early
Pacing-induced Left Ventricular Dysfunction Using
Myocardial Contrast Echocardiography
Shiro Nozaki, Anthony N. DeMaria. Valmik Bhargava. Bruno Cotter, H.
Kirk Hammond. UCSD and VAMC-San Diego, CA
Sustained rapid left ventricular ILV) pacing has been used to induce conges-
tive heart failure, but whether regional myocardial perfusion contributes to
the development of myocardial dysfunction is unknown. Therefore, we ex-
amined 4 pigs before and sequentially during sustained rapid LV pacing (225
bpm) from the at posterolateral epicardium. We performed myocardial con-
trast echocardiography (MCE) with left atrial injection of an investigational
galactose contrast agent prior to pacing and daily for 4 days after onset of
pacing. Pacemakers were inactivated for 60 min prior to data acquisition.
The ratio of peak intensity after injection and baseline intensity of region of
interest (peak intensity ratio) was measured at 8 segments (Fig) in the short
axis view at the tip of papillary muscle using video intensitometry. Percent
wall thickening I%WTh) in the interventricular septum (IVS) and posterolat-
eral wall (PLW) were assessed by M-mode echo. Over the 4 days of pacing,
the peak intensity ratio progressively decreased in the PLW [region 4 (p <
0.01). 5 (p < 0.001),6 (p < 0.051] but did not decrease in other regions. Sig-
nificant regional-specific changes were observed between region 4 vs 8 (p <
0.0002). and region 5 vs 8 (p < 0.0001). Similarly, %WTh in the PLW progres-
sively decreased (p < 0.0001) but was unchanged in the IVS. Conclusion:
These data suggest that sustained rapid LV pacing produces regional my-
ocardial dysfunction in the initial development of LV failure. Myocardial con-
trast echocardiography suggests that relative hypoperfusion may contribute
to regional myocardial dysfunction in this model.
1752-41 Transient Intracoronary Infusion of ATP After
Reperfuslon Reduces the Extent of No-reflow and
Infarct Size in Dogs
Kazuo Komamura. Hiroshi Ito 1, Shin Takiuchi 1, Katsuomi Iwakura 1,
Atsushi Maruyama 1, Tohru Masuyama, Tetsuo Minamino. Koichi Node,
Masafumi Kitakaze. Masatsugu Hori. The 1st Dept ofMed.. Osaka Univ, School of
Med., Osaka, Japan; 1 Sakurabashi Watanabe Hospital. Osaka, Japan
It is now widely acknowledged that preconditioning (PC) before severe is-
chemic insults reduces infarct size (IS) and may attenuate the extent of no-
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Microcirculatory Flow Dynamics During Peripheral
Intravenous Injection of Echogen'": Microscopic
Visualization of Mesenteric Microcirculatory Flow
with Simultaneous Transthoracic Echo Imaging in
Cats
Shuping Ge. George G. Giraud. Takahiro Shiota, George A. Pantely, Jinping Xu,
Zheng Gong. Masahiro Ishii, Xiaodong Zhou. Arthur Hall, David J. Sahn. Oregon
Hlth Sci Univ, Portland. OR
Echogen '" , a phase shift. fluorocarbon gas echo contrast agent, has been
shown capable of producing left ventricular and robust myocardial opaci-
fication, persisting up to 35 to 40 mm after peripheral venous injection.
We investigated the microcirculatory flow dynamics of this agent in the cat
mesenteric vascular bed using microscopic visualization of capillary flows.
Four cats (weight 2 to 5.2 kg, mean = 3.2 kg) were anesthetized and ven-
tilated. Systemic arterial blood pressure was monitored by cannulation of
the carotid artery. Microscopic examination (x 400) with an instrument cali-
brated for scale was performed by placing a loop of small intestine on awarm
water bath stage and transilluminating the mesentery with a xenon light
source while videotape recording the images for off-line analysis. Transtho-
racic echocardiography was performed simultaneously using a TOSHIBA
140A system with a 7 MHz transducer. Doses of 0.4, 06, 0.8 mllkg la total of
15 injections) of Echogen were administered intravenously. For all the injec-
tions, visually apparent left ventricular and intense myocardial opacification
was achieved lasting up to 20 minutes. A transient drop in arterial blood pres-
sure (25 ± 13.2 mmHg) was observed with the high dose 10.8 ml/kg). which
returned to baseline within 5 mins. Capillary flow velocities of the red blood
cells before and after Echogen injection were 4.3 ± 1.7 mmlsec dropping to
2.3 ± 0.9 mm/sec, the drop occurred 5 to 20 seconds following injections
and recovery was within 40-70 seconds. Transient slowing and periodicity
of flow was noted in the venule side of the capillaries. but arteriolar capil-
lary flow changed little during brisk transit of the observed bubbles. There
was no significant difference in flow velocity changes associated with differ-
ent doses (p > 0.05). Also, margination and endothelial adhesion of bubbles
observed in larger arteriolar feeding vessels without slowing of central RBC
flow suggests a mechanism for the long persistence of echo contrast bub-
bles in the tissue without vascular blockage or evidence of myocardial tissue
damage.
Clinical Applications of Myocardial Contrast
Echocardiography
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1752-21 Intra-coronary Contrast Echocardiography Predicts
Myocardial Viability Prior to PTCA
Martyn Thomas, Ray Wainwright. Stephen Holmberg. Richard Wray, David Jewitt.
Mark Monaghan. King's College Hospital, London, UK
A rapid method for predicting myocardial viability prior to revascularisation
remains elusive. Intra-coronary contrast echocardiography (ICE) evaluates
myocardial perfusion and may have a role in predicting myocardial viability by
demonstrating flow at a microvascular level. ICE was performed before PTCA
in 14 patients who had a wall motion abnormality associated with the index
artery (LAD = 11 RCA = 3). There were 10 men and 4 women with a mean
age of 63 years (range 54-74 years). Echo derived wall motion score and
global ejection fraction were calculated before PTCA and again at 1 month.
